secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001628280-24-034277
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M
--------------------------------------------------------------------------------

- Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.
- Net loss GAAP $85.6M ($1.47/sh) includes $45M Biopharma impairment; adjusted net loss $40.6M.
- Adjusted EBITDA improved to $(22.0)M from $(29.6)M YoY; orders grew to $85.3M.
- FY2024 revenue guidance raised to ~$310-311M; gross margin guidance ~42% (high end).
- SynBio revenue $33.0M, NGS $43.4M, Biopharma $5.1M; cash $289.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024034277/0001628280-24-034277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024034277/twist-20240802.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer